Please login to the form below

Not currently logged in
Email:
Password:

neuroendocrine

This page shows the latest neuroendocrine news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Novartis: pipeline will generate 60 filings in three years

The company will also highlight its radioligand portfolio, currently headed by Lutathera (. 177. Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours, which was recently bolstered by the $2.1bn acquisition of

Latest news

  • Novartis buys cancer specialist Endocyte for $2.1bn

    177. Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours, acquired along with French company Advanced Accelerator Applications for $3.9bn a year ago.

  • Novartis launch NET cancer community app Novartis launch NET cancer community app

    Following its release of a remote clinical trial app, Novartis has honed in on digital once again, this time launching an app designed to support the Neuroendocrine Tumour (NET) cancer community.

  • AAA board presses go on $3.9bn Novartis takeover AAA board presses go on $3.9bn Novartis takeover

    With the acquisition, Novartis is aiming to add AAA’s Lutathera (Lutetium Lu177 dotatate) for treating gastroenteropancreatic neuroendocrine tumours (NET) – approved in the EU and heading for an FDA decision towards

  • Novartis to buy French radiopharma specialist AAA for $3.9bn Novartis to buy French radiopharma specialist AAA for $3.9bn

    The Swiss pharma giant said this morning that the deal would help strengthen its cancer therapy businesses, adding an approved radiopharmaceutical drug - Lutathera (177Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours

  • AAA’s orphan drug Lutathera wins EU green light AAA’s orphan drug Lutathera wins EU green light

    Advanced Accelerator Applications’ (AAA) Lutathera (lutetium oxodotreotide) has received European approval to treat adults with unresectable or metastatic, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours. ... Known as

More from news
Approximately 1 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Last year the firm’s oncology portfolio accounted for 57% of its 1.6bn group sales, bringing in 904.8m with Somatuline (lanreotide) - a treatment for neuroendocrine tumours as well as ... leadership in neuroendocrine tumours - any therapeutic solutions

  • Charting a course for expansion Charting a course for expansion

    The drug treats the hormonal disorder acromegaly and neuroendocrine tumours (NETs), a rare form of cancer.

  • Pharma deals during September 2013 Pharma deals during September 2013

    from Camarus, paying an undisclosed milestone included in their $700 million deal signed two years ago for the indications acromegaly and neuroendocrine tumours.

  • Pharma deals during February 2013 Pharma deals during February 2013

    Roche has acquired an exclusive licence from Chiasma for Octreolin (in phase III), an orphan designated oral treatment in US for acromegaly with a neuroendocrine tumour indication to follow.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics